The mechanism of conversion of angiotensin I to angiotensin II was studied in vivo in the pulmonary circulation of the intact anesthetized dog and in vitro in plasma by using L-Leu-angiotensin I, D-Leu-angiotensin I, and des-Leuangiotensin I which had been synthesized by the solid-phase technique. None of the peptides were active in the rabbit aortic strip preparation; D-Leuangiotensin I and des-Leu-angiotensin I gave less than 5$ of the pressor response of L-Leu-angiotensin I in the pentolinium-treated rat. D-Leuangiotensin I and des-Leu-angiotensin I were not converted to angiotensin II when incubated with diluted human or dog plasma or partially purified converting enzyme from hog plasma. In a single pulmonary circulation time, following injection of a 20-nmole bolus of L-Leu-angiotensin I into the dog right ventricle, 56S£ of the material recovered had been converted to angiotensin II, as measured by radioimmunoassay. Conversion was accompanied by a rise in mean blood pressure of 30 mm Hg. After injection of equimolar amounts of D-Leu-angiotensin I and des-Leu-angiotensin I, no generation of angiotensin II and no pressor response occurred. These observations indicate that pulmonary conversion in vivo and plasma conversion in vitro occur via a dipepridylcarboxypeptidase and that a r>amino acid at the C-terminus prevents conversion.
• Previous studies from our laboratory (1) showed that supraphysiological amounts of angiotensin I (AI) could be converted to angiotensin II (All) in a single passage through the pulmonary capillary bed of the dog. The rate of conversion was much more rapid in lung than in whole blood or plasma alone. Identification of metabolites indicated that the mechanism of plasma and organ conversion might differ. The present study was undertaken to further characterize the mechanism of conversion of AI to All in the dog lung by using synthetic analogs of AI.
Methods

PEPTIDE SYNTHESIS
l-Asp-5-Ile-lO-L-Leu-angiotensin I (L-Leu-AI), l-Asp-5-Ile-10-D-Leu-angiotensin I (r>Leu-AI) and the nonapeptide l-Asp-5-Ile-10-des-Leu-angiotensin I (des-Leu-AI) were synthesized manually by the solid-phase technique (2, 3) . T-butyloxycarbonyl (t-Boc)-D-leucine was synthesized by the technique of Schwyzer (4) . Figure 1 summarizes the steps in synthesis, including the sequences of the products with their blocking groups. The basic procedure described by Stewart and Young (3) was followed. In addition, at the end of each deprotection and of each coupling step, the reaction was checked for completion by a 3minute ninhydrin reaction (5) . Flow diagram for peptide synthesis. tBoc = t-butyloocycarbonyl; Bzl = benzyl; Z = carbobenz oxy; Et n N = triethylamine; NH 4 AC = ammonium acetate.
reaction was incomplete after 2 hours, the coupling step was repeated. Failure to achieve complete coupling after a second reaction was followed by acetylation of the unreacted amino group and consequent stopping of the chain growth. Coupling was carried out in methylene chloride; t-Boc-NO 2 -Arg, which is insoluble in methylene chloride, was first solubilized in a minimal volume of dimethylformamide. After completion of the peptide chain, the last t-Boc was removed, and the resin was neutralized and dried. The peptide was cleaved from the resin with HF in the presence of anisole. The peptide-resin mixture was washed dioroughly with ethyl acetate to remove excess anisole, and the peptide was extracted out in dilute acetic acid. Approximately 300 tng of L-Leu-AI, D-Leu-AI, or des-Leu-AI were dissolved in water and chromatographed on a CM Sephadex C25 column (15 cm by 0.6 cm) using an ammonium acetate (NH 4 AC) gradient system ( Fig. 2 ). After the sample was applied, the column was washed with 25 ml of 0.02M NH 4 AC; 367 ml of 0.02M NH 4 AC in a 1000-ml aspirator bottle and 150 ml of 1.0M NH 4 AC in a 250-ml aspirator
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bottle gave the required gradient. A flow rate of 0.25 ml/min was maintained with a Sigma motor pump. The purified sample was then lyophilized and desalted on either Biogel P-2 or Sephadex G-10 in 0.05M HAC. Final yields were 30-35$.
BIOASSAY
L-Leu-AI, D-Leu-AI, and des-Leu-AI were bioassayed with the rabbit aortic strip (6), the pentolinium-treated rat, and the pentobarbitalanesthetized dog. In the rat pressor assay, the technique of Gunnels et al. (7) was used except that the animals were not nephrectomized. Ganglionic blockade was achieved with pentolinium tartrate (3.5 mg/kg). Test injections were preceded and followed by known doses of standard l-Asp-5-Ile-10-L-Leu-AI using the fourpoint assay method. Intact dogs were anesthetized with pentobarbital (15 mg/kg); peptides were injected intravenously, and pressure was measured from a large-bore catheter in the abdominal aorta.
RADIOIMMUNOASSAY
The L-Leu-AI, D-Leu-AI, and des-Leu-AI were subjected to radioimmunoassav with antibodies to AI (8) and All (9) . The amount of peptide required to produce 50% displacement with a given antibody was determined and compared with the amount of homologous peptide required to do so. The ratio represents percent crossreactivity.
IN VITRO METABOLISM
Converting Enzyme.-L-Leu-AI, D-Leu-AI, and des-Leu-AI (50 pmoles) were added to 250 liters of 0.05M NH 4 AC buffer containing 0.1M NaCl and 0.5 mg of partially purified converting enzyme from hog plasma 1 (10) and incubated in a water bath at 37°C. The final concentration of each peptide was 200 pmoles/ml. Aliquots of 30 /xliters were removed at 0, 15, 30, and 60 minutes and at 6 and 24 hours and added to iced tubes containing 2.6 mM EDTA, 1.6 mM dimercaptol, and 3.4 mM 8-OH-quinoline (final concentration). The samples were frozen and later subjected to radioimmunoassay for angiotensin I (8) and II (9) .
Plasma.-Samples (15 ml) of blood were drawn from the femoral veins of pentobarbitalanesthetized dogs into iced 20-ml glass tubes containing heparin (143 USP units) or sodium citrate (0.5 ml of 3.8% solution). Samples were spun immediately at 4°C in a refrigerated centrifuge, and the plasma fraction was removed. Each ml of plasma was diluted 1:3.5 with 0.1M tris acetate buffer, pH 7.4, containing 0.1M NaCl, as suggested by Poulsen and Poulsen (11) . Samples of human plasma were prepared similarly. To 5 ml of diluted plasma were added 100 pmoles of L-Leu-AI, r>Leu-AI, des-Leu-AI, or ] Gift of Dr. Frederic Dorer, Cleveland, Ohio. Peptide purification. L-Leu-AI, D-Leu-AI, and des-Leu-AI were ehtted at the same position on the gradient. All contaminating peptides were eluted at a lower conductivity.
All, giving a starting concentration of 20 pmoles/ ml. Aliquots of 500 ^.liters were removed at frequent intervals, immediately cooled to 4°C, and treated with the enzyme inhibitors listed previously. Samples were then frozen and subjected to radioimmunoassay for AI and All.
IN VIVO METABOLISM
Six mongrel dogs of both sexes weighing 15-20 kg were anesthetized with pentobarbital (30 mg/kg) placed on a respirator (Harvard), and maintained in deep anesthesia with Fluothanc and oxygen. Each dog was given intravenous heparin (1000 U/kg). A Swan-Ganz catheter (12) was advanced into die pulmonary artery, as verified by the contour of the pressure tracing, then withdrawn until the diastolic pressure fell to 0-5 mm Hg and a typical right ventricular pressure tracing was obtained. The catheter was left in the right ventricle for the remainder of the experiment. Large-bore retrograde catheters were placed in the ascending and abdominal aorta. Blood pressure was continuously monitored from the catheter in the abdominal aorta by a pressure transducer (Hewlett-Packard) and recorded on a 6-channel direct-writing oscillograph (Hewlett-Packard). L-Leu-AI, D-Leu-AI, or des-Leu-AI (20 nmoles) was injected as a single bolus into the right ventricle. Blood was collected in six sequential 12-ml aliquots from the ascending aorta at 5-second intervals following injection and then at 1, 2, and 5 minutes. A series of plastic syringes connected via a manifold system and containing EDTA, dimercaptol, and 8-OH-quinoline in the amounts described above were used for collection. Samples were processed and analyzed as previously described for plasma. The second and third sequential samples obtained 5-15 seconds after injection represented one circulation through the lung as determined by appearance time of immunoreactive material.
Results
PEPTIDE CHARACTERIZATION
Axnino acid analyses were performed on a Beckman analyzer after hydrolysis with 5.7N HC1 for 24 hours at 110°C or after enzymatic digestion with papain and aminopeptidase M (3). Table 1 summarizes the results. Acid hydrolysis yielded the amino acids in the expected ratio. After digestion with papain and aminopeptidase M, L-Leu-AI was completely digested. D-Leu-AI was only partially digested: the pentapeptide His-Pro-Phe-His-Leu survived intact. This result is compatible with the inability of aminopeptidases to cleave the imide bond of proline (13) and the inhibition of papain hydrolysis by D-residues (14) . Des-Leu-AI was partially digested: the dipeptide His-Pro survived intact. This may be due to inhibition of papain hydrolysis by peptides containing Phe as the penultimate residue (15) . Quantitative recovery of Phe and His from des-Leu-AI was obtained after digestion with carboxypeptidase A.
One mg of each peptide was dissolved in 30 /xliters of 0.1M HAC, spotted on Whatman 3MM paper, and subjected to chromatography in a butanol: acetic acid: water (4:1:5) system for 24 hours followed by electrophoresis in a second dimension at 4000 v for 1 hour at pH 3.6 in pyridine acetate buffer. Each peptide produced a single spot with ninhydrincollidine stain.
To evaluate D-Leu-AI for racemization during synthesis, D-Leu-AI and L-Leu-AI were incubated with carboxypeptidase A at an enzyme-substrate ratio of 1 to 300 in 0.1M NH4AC at pH 8.0 at 22°C for 4 minutes. The samples were immediately lyophilized and subjected to amino acid analysis. The L-Leu-AI digestion produced Leu, His, and Phe in molar quantities equal to the quantity of peptide incubated. The D-Leu-AI digestion produced no detectable amino acids, indicating that there was no measurable L-leucine at the carboxyl terminus of the peptide.
Des-Leu-AI was evaluated for potential biological activity by incubation with carboxypeptidase A at an enzyme-substrate ratio of 1 to 2000 in 0.1M NH4AC at pH 8.0 at 22°C for 5 minutes. Aliquots were removed at l-minute intervals, immediately treated with 8-OHquinoline (final concentration 3.4 mM), and lyophilized. The samples were assayed for pressor activity in a pentobarbital-anesthetized dog. Control untreated des-Leu-AI gave 5% of the pressor response of an equimolar amount of All. The 3-minute sample gave the maximal pressor response, 922? of the pressor response of All. Amino acid analysis of the 3minute sample showed release of 91% of the Cterminal His and no free Phe, confirming nearly quantitative generation of AH.
BIOASSAY
In the rabbit aortic strip preparation, L-Leu-AI, D-Leu-AI, and des-Leu-AI had less than 5% of the activity of an equimolar amount of AIL This approaches the lower limit of sensitivity of our bioassay preparation. AI has been found by others (16) to give a similar (5% of control AH response) contractile response in this system. Most of the apparent intrinsic biological activity was abolished by infusing a peptide inhibitor of AI conversion, suggesting that the activity was largely the result of in situ conversion of AI to AH. In the pentolinium-treated rat ( Table 2) , L-Leu-AI gave 11635 of the pressor response of commercial AI; des-Leu-AI gave 3% of the pressor response of L-Leu-AI; D-Leu-AI gave 335 of the pressor response of L-Leu-AI. Responses were linear when pressure changes were 0-25 mm Hg.
TABLE 1
AmtTio Acid Analyses of i^-Leu-AI, D-Leu-AI, and des-Leu-AI Asp Arg Val L-Leu-AI* L-Leu-AI* L-Leu-AIf L-Leu-AIf D-Leu-AI D-Leu-AI des-Leu-AI des-Leu-AI In the pentobarbital-anesthetized dog, L-Leu-AI gave 110% of the pressor response of commercial AI; des-Leu-AI gave 5-7% of the pressor response of L-Leu-AI; D-Leu-AI gave 2-6% of the pressor response of L-Leu-AI.
RADIOIMMUNOASSAY
The displacement curves for L-Leu-AI, D-Leu-AI, des-Leu-AI, and All with anti-AI are shown in Figure 3 and with anti-All, in Figure 4 . The concentration of each peptide at 50% displacement and the percent cross-reactivity are summarized in Table 3 . The high degree of cross-reactivity between D-and L-Leu-AI made radioimmunoassay using anti-AI and 125 I-L-Leu-AI as a tracer a useful measure of D-Leu-AI concentration in plasma. The low degree of cross-reactivity between des-Leu-AI and both anti-AI and anti-All made measurement of des-Leu-AI in plasma by radioimmunoassay impossible. Neither D-Leu-AI nor des-Leu-AI reacted with anti-All sufficiently to confuse metabolic studies in which All generation was being evaluated.
IN VITRO METABOLISM
Converting Enzyme.- Figure 5 summarizes the metabolism of L-Leu-AI, D-Leu-AI, and All with partially purified converting enzyme from hog plasma. Incubation with L-Leu-AI for 6 hours yielded levels of AH which approached 40% of the starting molar concentration of AI. Incubation of All under these conditions led to the loss of 55% of the starting material. The action of angiotensinases did not permit quantitative estimation of conversion because of loss of All during the long incubation. D-Leu-AI and des-Leu-AI were not converted to All. D-Leu-AI was vulnerable to angiotensinases; it disappeared during incubation. The concentration of des-Leu-AI could not be measured by radioimmunoassay.
Plasma.- Figure 6 tion of L-Leu-AI with dog plasma generated demonstrable levels of All within 4 minutes; the level was still rising when the incubation was stopped at 30 minutes. Results in citrated dog plasma were identical. In heparinized human plasma, All appeared with the same time course as in dog plasma, but achieved levels two and a half times as high. Incubation of All in dog plasma under identical conditions led to the loss of 25% of the starting material at 30 minutes. D-Leu-AI and des-Leu-AI were not converted to All in either human or dog plasma.
IN VIVO METABOLISM
After injection of L-Leu-AI, 56 ± 7% (mean ± S E ) of the immunoreactive material appearing in the pulmonary effluent within a In vitro metabolism with partially purified converting enzyme from plasma. The disappearance of AI immunoactivity and appearance of AH activity are plotted against time. Starting concentration of each peptide was 200 pmoles/ml. D-Leu-AI concentrations were determined using the L-Leu-AI radiotmmunoassay with appropriate correction. single circulation time was All; the remainder was unchanged AI. Table 4 summarizes the results for six animals. After injection of D-Leu-AI and des-Leu-AI, no All was generated. All of the measured All in the pulmonary effluent could be accounted for by cross-reactivity with anti-All. In all animals, arterial levels of both AI and All returned to normal within 5 minutes of injecting either Lor r>-Leu-AI.
The calculated total recovery of immunoreactive material in the pulmonary venous effluent after injection of L-Leu-AI was 50-55% of the total peptide injected, based on an estimated pulmonary blood flow (1) .
Following injection of L-Leu-AI, all dogs had a pressor response within 15 seconds which lasted for 3 minutes. Systolic pressures increased by 28 ± 3 mm Hg (mean±SE); diastolic pressures increased by 34 ± 4 mm Hg. D-Leu-AI and des-Leu-AI produced no pressor response.
Discussion
Immunologic evaluation of the peptide analogues of angiotensin I synthesized for this study has emphasized the importance of the carboxyl terminal amino acid for antigenic specificity. The substitution of r>Leu for L-Leu in the tenth position resulted in the loss of 56% of reactivity with anti-AI. Deletion of the Cterminal amino acid led to the loss of 90% of reactivity with anti-AI and a 30-fold increase in activity with anti-All. Deletion of residues 9 and 10 (formation of angiotensin II) caused the loss of 99.5% of reactivity with anti-AI, In vitro metabolism in diluted plasma. The level of All activity is plotted against time. Starting concentration of each peptide was 20 pmoles/ml. All concentrations were determined by radioimmunoassay.
Previous work has indicated that the Cterminus is also important for specificity in the AII-anti-AII system (17) (18) (19) . A single D-amino acid substitution at the Cterminus does not abolish the susceptibility of the molecule to angiotensinases. Although no conversion of D-Leu-AI or des-Leu-AI occurred with plasma converting enzyme, the decapeptide disappeared from plasma with time. The rates of disappearance of D-and L-Leu-AI in the intact dog were similar. Endopeptidases and aminopeptidases probably account for the observed losses. D-Leu-AI provides an unusual opportunity to observe the effects of angiotensinases on AI in the absence of conversion.
This study has defined some structural requirements for angiotensin-converting enzyme in the lung in vivo and in plasma in vitro. Within 15 seconds of injecting a large bolus of L-Leu-AI into the right ventricle, high levels of All were measurable by radioimmunoassay in aortic blood and a pressor response observed. Equimolar amounts of D-Leu-AI and des-Leu-AI yielded no All and no increase in blood pressure. When incubated with diluted plasma or partially purified plasma converting enzyme, L-Leu-AI generated All. D-Leu-AI and des-Leu-AI were nonreactive under identical conditions. Previous work (1) had indicated that leucine was the major metabolic product of pulmonary conversion and histidyl leucine of plasma conversion. This suggested monocarboxypeptidase activity for pulmonary converting enzyme and dipeptidylcarboxypeptidase activity for plasma converting enzyme. To test this hypothesis, des-Leu-AI and r>Leu-AI were synthesized. Des-Leu-AI would be suitable substrate for a converting enzyme of the (20) heptapeptide. The failure of conversion of des-Leu-AI to All in both lung and plasma supports a common dipeptidylcarboxypeptidase mechanism of conversion. The predominance of leucine in the pulmonary effluent in earner studies was probably due to secondary cleavage of His-Leu by dipeptidases or aminopeptidase. These observations support the experiments of Lentz et al. (20) , who demonstrated that des-Leu-AI prepared by partial digestion of L-Leu-AI with carboxypeptidase A had no pressor activity in the rat.
Other studies of the mechanism of in vivo pulmonary conversion have pointed to dipeptidylcarboxypeptidase activity. The undecapeptide 5-Ile-9-His-10-His-ll-Leu angiotensin I did not produce contraction of the rat colon either before or after passage through the lung of dog or cat (21) . Removal of the dipeptide histidylleucine from angiotensin I had been demonstrated in the rat lung perfused with Krebs solution (22) .
A dual enzymatic mechanism for handling AI in the rat lung has been proposed: dipeptidylcarboxypeptidase at near physiologic substrate levels and monocarboxypeptidase at extremely high substrate levels (23) . Concentrations of L-Leu-AI and of des-Leu-AI achieved in our study fit into the near physiologic range, in which a dipeptidylcarboxypeptidase mechanism would be expected. Activation of a monocarboxypeptidase mechanism at higher substrate levels does provide an alternate explanation for the predominance of leucine in the pulmonary effluent in our earlier studies (1), which were done at ten times greater substrate levels. Further studies using higher concentrations of des-Leu-AI and radioactive labeling would be necessary to resolve the issue.
The inability of D-Leu-AI to be converted to All either in the pulmonary circulation or in Circulation Rutorch, Vol. XXIX, Dtctmbtr 1971 plasma indicates that a conformational change at the tenth position prevents both pulmonary and plasma converting enzymes from attacking the peptide. Previous work (24) , in which 5-Val-9-Pro-10-Phe-AI was found not to be a pressor agent in vivo, indicated that the structure of the C-terminal dipeptide was important in the conversion reaction. Specificity of converting enzymes does not seem to extend to the amino terminal end of the peptide. Lung and plasma extracts which have angiotensin-converting activity have been shown to cleave a variety of artificial substrates. Partially purified converting enzyme from the lung (25) cleaves hippuryl-L-His-L-Leu (Hip-L-His-L-Leu) at about 10% of the rate at which it converts L-Leu-AI to AIL Plasma converting enzyme also cleaves His-Leu from Hip-L-His-L-Leu (10, 26), although less efficiently than from L-Leu-AI.
The plasma enzyme also cleaves dipeptides from a number of substrates of varied structure, indicating broad specificity (26) (27) (28) , although the kinetics of cleavage with various substrates differ greatly. The range of specificity of pulmonary converting enzyme in vivo has not yet been defined. It may or may not be similar to that of plasma converting enzyme. This study indicates, however, that both are dipeptidylcarboxypeptidases.
